Literature DB >> 31711642

LncRNA LINC00470 promotes the degradation of PTEN mRNA to facilitate malignant behavior in gastric cancer cells.

Jijun Yan1, Xiufang Huang1, Xiongjie Zhang1, Zhijie Chen1, Chao Ye1, Wencai Xiang1, Zhengbin Huang2.   

Abstract

Gastric cancer (GC) is the fourth most frequent malignancy worldwide. Recently, long noncoding RNA (lncRNA) LINC00470 has been demonstrated to play an oncogenic role in human cancer. However, the clinical significance and functional role of LINC00470 in the progression of GC is largely unknown. In this study, our findings showed that LINC00470 was significantly upregulated in GC tissues and cell lines, and correlated with distant metastasis, TNM stage and poor prognosis. Overexpression and knockdown experiments revealed its oncogenic functions on GC cell proliferation, migration and invasion. Mechanistically, LINC00470 associated with PTEN mRNA and suppressed its stability through interaction with the N6-methyladenosine (m6A) writer METTL3. We also showed that LINC00470-METTL3-mediated PTEN mRNA degradation relied on the m6A reader protein YTHDF2-dependent pathway. Taken together, LINC00470 might serve as a therapeutic target for GC patients.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  METTL3; YTHDF2; m(6)A modification; mRNA stability

Mesh:

Substances:

Year:  2019        PMID: 31711642     DOI: 10.1016/j.bbrc.2019.11.016

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  32 in total

1.  METTL3 potentiates progression of cervical cancer by suppressing ER stress via regulating m6A modification of TXNDC5 mRNA.

Authors:  Qiu-Ying Du; Fu-Chun Huo; Wen-Qi Du; Xiao-Lin Sun; Xin Jiang; Lan-Sheng Zhang; Dong-Sheng Pei
Journal:  Oncogene       Date:  2022-08-20       Impact factor: 8.756

Review 2.  Progress and application of epitranscriptomic m6A modification in gastric cancer.

Authors:  Yitian Xu; Chen Huang
Journal:  RNA Biol       Date:  2022-01       Impact factor: 4.766

3.  Silencing of YTHDF1 Attenuates Cerebral Stroke by Inducing PTEN Degradation and Activating the PTEN/AKT/mTOR Pathway.

Authors:  Xiaohong Li; Peng An; Fang Han; Meihong Yu; Zhenfei Yu; Ying Li
Journal:  Mol Biotechnol       Date:  2022-10-19       Impact factor: 2.860

Review 4.  RNA Epigenetics: Fine-Tuning Chromatin Plasticity and Transcriptional Regulation, and the Implications in Human Diseases.

Authors:  Amber Willbanks; Shaun Wood; Jason X Cheng
Journal:  Genes (Basel)       Date:  2021-04-22       Impact factor: 4.096

Review 5.  RNA methylation in hematological malignancies and its interactions with other epigenetic modifications.

Authors:  Lan Yao; Hua Yin; Mei Hong; Yajun Wang; Tingting Yu; Yao Teng; Tingting Li; Qiuling Wu
Journal:  Leukemia       Date:  2021-03-25       Impact factor: 12.883

Review 6.  Emerging role of RNA methyltransferase METTL3 in gastrointestinal cancer.

Authors:  Qiang Wang; Wei Geng; Huimin Guo; Zhangding Wang; Kaiyue Xu; Chen Chen; Shouyu Wang
Journal:  J Hematol Oncol       Date:  2020-05-19       Impact factor: 17.388

7.  Hub Long Noncoding RNAs with m6A Modification for Signatures and Prognostic Values in Kidney Renal Clear Cell Carcinoma.

Authors:  Gaoteng Lin; Huadong Wang; Yuqi Wu; Keruo Wang; Gang Li
Journal:  Front Mol Biosci       Date:  2021-07-06

Review 8.  Long non-coding RNAs in gastric cancer: New emerging biological functions and therapeutic implications.

Authors:  Huidan Tan; Shouyue Zhang; Jin Zhang; Lingjuan Zhu; Yanmei Chen; Hongmei Yang; Yi Chen; Yang An; Bo Liu
Journal:  Theranostics       Date:  2020-07-11       Impact factor: 11.556

Review 9.  Novel insights into the interplay between m6A modification and noncoding RNAs in cancer.

Authors:  You-Cai Yi; Xiao-Yu Chen; Jing Zhang; Jin-Shui Zhu
Journal:  Mol Cancer       Date:  2020-08-07       Impact factor: 27.401

Review 10.  Roles of METTL3 in cancer: mechanisms and therapeutic targeting.

Authors:  Chengwu Zeng; Wanxu Huang; Yangqiu Li; Hengyou Weng
Journal:  J Hematol Oncol       Date:  2020-08-27       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.